APX 3330

Drug Profile

APX 3330

Alternative Names: APX3330; E-3330

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Apexian Pharmaceuticals
  • Class Antivirals; Hepatoprotectants; Quinones; Small molecules
  • Mechanism of Action DNA apurinic apyrimidinic site lyase inhibitors; Protein inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pancreatic cancer
  • Discontinued Liver disorders

Most Recent Events

  • 24 Oct 2016 ApeX Therapeutics is now called Apexian Pharmaceuticals
  • 20 Jun 2016 ApeX Therapeutics files an IND application with the US FDA in USA for Pancreatic cancer
  • 12 May 2016 Pharmacodynamics data from a preclinical study in Pancreatic cancer and adverse events data from clinical studies in Liver disorders released by Apex Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top